In a strategic move to solidify its dominance in the burgeoning field of oral anti-inflammatories, Eli Lilly and Company (NYSE:LLY) announced on January 7, 2026, a definitive agreement to acquire Ventyx Biosciences (NASDAQ:VTYX) for approximately $1.2 billion. The all-cash deal, valued at $14.00 per share, marks
In a landmark shift for the biotechnology and pharmaceutical industries, the U.S. Food and Drug Administration (FDA) has officially entered what experts call the “Enforcement Era” of artificial intelligence. Following the release of the January 2026 Joint Principles in collaboration with the European Medicines Agency (EMA), the FDA has unveiled a rigorous new regulatory framework [...]
In the annals of scientific history, few moments represent a clearer "before and after" than the arrival of AlphaFold 3. Developed by Google DeepMind and its dedicated drug-discovery arm, Isomorphic Labs, this model has fundamentally shifted the paradigm of biological research. While its predecessor famously solved the 50-year-old protein-folding problem, AlphaFold 3 has gone significantly [...]
Under the terms of the deal between Seamless Therapeutics and Eli Lilly, Seamless will design and program site-specific enzymes to correct mutations in certain genes related to hearing loss.
In a decisive move to solidify its leadership in the next generation of chronic inflammation and cardiometabolic treatments, Eli Lilly and Company (NYSE: LLY) announced the acquisition of Ventyx Biosciences (NASDAQ: VTYX) for approximately $1.2 billion. The all-cash deal, announced in early January 2026, values Ventyx at $14.00
In the quest to cure humanity’s most devastating diseases, the bottleneck has long been the "wet lab"—the arduous, years-long process of trial and error required to find a protein that can stick to a target and stop a disease in its tracks. However, a seismic shift occurred with the maturation of AlphaProteo, a generative AI [...]
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages.
Just because a business is in the green today doesn’t mean it will thrive tomorrow.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Ocular Therapeutix (NASDAQ:OCUL) and the rest of the pharmaceuticals stocks fared in Q3.
The year 2024 marked a historic inflection point in the history of science, as the Royal Swedish Academy of Sciences awarded Nobel Prizes in both Physics and Chemistry to pioneers of artificial intelligence. This dual recognition effectively ended the debate over whether AI was merely a sophisticated tool or a fundamental branch of scientific inquiry. [...]
The biotechnology sector has always been a high-stakes arena where clinical success can create multi-billion-dollar empires overnight, and a failed negotiation can erase a fifth of a company’s market value in a single trading session. This volatility was on full display in late January 2026 as Revolution Medicines (Nasdaq: RVMD) experienced a dramatic 20% stock [...]
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities.
However, their paths to becoming $100 billion corporations are ripe with competition, ranging from giants with vast resources to agile upstarts eager to disrupt the status quo.
